<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855335</url>
  </required_header>
  <id_info>
    <org_study_id>CR015442</org_study_id>
    <secondary_id>TMC114HIV3015</secondary_id>
    <nct_id>NCT00855335</nct_id>
  </id_info>
  <brief_title>A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women</brief_title>
  <official_title>A Single Arm, Open Label Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Scientific Affairs, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to study how changes in the body during pregnancy influence the
      blood levels of TMC114 (darunavir) and ritonavir taken together, darunavir and cobicistat
      taken as a fixed-dose combination, TMC125 (etravirine) taken alone or with darunavir and
      ritonavir or rilpivirine in patients with human immunodeficiency virus-1 (HIV-1). This study
      will examine how these drugs are absorbed in the body, how they are distributed within the
      body and how they are removed from the body over time. Any pregnant woman who is currently
      receiving darunavir with ritonavir, darunavir with cobicistat, etravirine or rilpivirine for
      HIV-1, and who meets the eligibility criteria for the study, will be allowed to enroll.
      Patients must be willing to remain on study medication during the course of their pregnancy,
      and 12 weeks postpartum. The information collected may help answer questions about how to
      best prescribe these three drugs for pregnant women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are many biological changes that occur during pregnancy, some of which may affect the
      way HIV medications are absorbed, distributed and removed within the body. Some medications
      have been used for HIV treatment during pregnancy, but little is known about how pregnancy
      affects the class of drugs being used in this study. To participate in this study, patients
      must be receiving 600mg of TMC114 (darunavir) taken with 100mg ritonavir twice daily or 800mg
      of TMC114 (darunavir) with 100mg of ritonavir once daily or 800 mg of darunavir taken with
      150mg of cobicistat taken once daily or 200mg of TMC125 (etravirine) (with or without
      darunavir/ ritonavir) taken twice daily or 25mg of TMC278 (rilpivirine) taken once daily plus
      additional antiretroviral drugs needed to construct an active antiretroviral regimen.
      Darunavir and ritonavir, darunavir and cobicistat, etravirine, or rilpivirine will be
      supplied to study participants. Darunavir and ritonavir are human immunodeficiency virus
      (HIV) protease inhibitors (PIs); cobicistat is a pharmacoenhancer which boosts the levels of
      darunavir but has no anti-HIV activity; etravirine and rilpivirine are non-nucleoside reverse
      transcriptase inhibitor (NNRTI) of HIV. Twelve-hour or twenty four-hour blood sampling will
      be done for each patient at each of three study visits: Visit 4 (2nd trimester), Visit 5 (3rd
      trimester), and Visit 8 (6-12 weeks postpartum). Eight blood draws will be taken during each
      visit: One prior to intake of study medication, and one for each of seven post-dose sampling
      time-points (hours 1, 2, 3, 4, 6, 9 and 12). The study is designed primarily to examine the
      pharmacokinetics of darunavir/ritonavir (darunavir/r), darunavir/ cobicistat, etravirine or
      rilpivirine during the second and third trimesters of gestation, as well as postpartum.
      Pharmacokinetics measures how the body absorbs, distributes and excretes medication. The
      study will also examine any changes in anti-viral activity during pregnancy, and the
      postpartum period. It will note any safety and tolerability of the medications used by the
      mother, and will measure the level of darunavir/ritonavir, darunavir/ cobicistat, etravirine
      or rilpivirine in the newborn's cord blood at the time of delivery; outcomes for both mother
      and child will be assessed as well. During the treatment period, patients will be seen at
      regular visits in the clinic, where the investigator will assess the patient's medical
      condition, any Adverse Events and study drug compliance. Laboratory evaluations for efficacy
      and safety will be done at regular visits as well as blood pressure monitoring. Up to
      forty-eight (48) HIV positive pregnant women will participate in this study. Study enrollment
      will be closed once 12 evaluable patients taking darunavir/ritonavir once daily, 12 evaluable
      patients taking darunavir/cobicistat once daily, 12 evaluable patients taking
      darunavir/ritonavir twice daily, 12 evaluable patients taking etravirine taking twice daily
      and 12 evaluable patients taking rilpivirine once daily have been enrolled. The study will be
      conducted at approximately 14 research centers in the United States and 1 in Puerto Rico. In
      order to participate, patients must be pregnant for 13-24 weeks. The primary purpose (or
      outcome) of the study is to assess the influence of pregnancy on the pharmacokinetics of
      darunavir/ritonavir, darunavir/ cobicistat, etravirine or rilpivirine during the second and
      third trimesters of gestation, as well as postpartum. Darunavir: One 600 mg or two 300 mg
      tablets taken twice daily by mouth (two or four tablets a day total). Ritonavir: 100mg tablet
      taken twice daily by mouth (two tablets a day total), together with darunavir. Darunavir: Two
      400 mg tablets taken once daily by mouth (two tablets a day total). Ritonavir: 100mg tablet
      taken once daily by mouth (one tablet a day total), together with darunavir. Darunavir/
      cobicistat: a fixed dose combination containing 800mg of darunavir and 150mg of cobicistat.
      Etravirine: Two 100 mg tablets taken twice daily by mouth (four tablets a day total).
      Rilpivirine: One 25mg tablet taken once daily by mouth (one tablet a day total). Study
      medication will be given from the baseline visit (second pregnancy trimester) until Visit 8
      (up to 12 weeks after delivery).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 9, 2009</start_date>
  <completion_date type="Actual">August 11, 2016</completion_date>
  <primary_completion_date type="Actual">August 11, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Predose (Trough) Plasma Concentration (C0h)</measure>
    <time_frame>Predose on Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
    <description>C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum Plasma Concentration (Cmin)</measure>
    <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
    <description>The Cmin is the minimum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
    <description>The Cmax is the maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Reach the Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
    <description>The Tmax is defined as actual sampling time to reach maximum observed plasma concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 Hours Post-dose (AUC0-12h)</measure>
    <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
    <description>The AUC (0-12) is the area under the plasma concentration-time curve from time zero to 12 hours post dose. The selected arms were based on the dosing frequency (twice daily).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h)</measure>
    <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
    <description>The AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post dose. The selected arms were based on the dosing frequency (once daily).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Plasma Viral Load (&lt;) 50 Copies/Milliliter (mL)</measure>
    <time_frame>Up to postpartum (6-12 weeks)</time_frame>
    <description>Number of participants were assessed with a viral load (VL) lesser than (&lt;) 50 HIV-1 RNA copies/ mL over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Log10 Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Viral Load Value</measure>
    <time_frame>Baseline, 4 weeks after baseline, 2nd and 3rd trimesters of pregnancy and postpartum (2-5 weeks and 6-12 weeks)</time_frame>
    <description>Mean change from baseline in log 10 HIV-1 RNA VL was assessed up to postpartum (6-12 weeks).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in CD4+ Cell Count</measure>
    <time_frame>Baseline, 4 weeks after baseline, 2nd and 3rd trimesters of pregnancy and postpartum (2-5 weeks and 6-12 weeks)</time_frame>
    <description>Mean Change From Baseline in CD4+ Cell Count were assessed for immunology testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Resistance at Virological Failure</measure>
    <time_frame>Up to follow-up phase (16 weeks after postpartum)</time_frame>
    <description>Resistance analysis was determined using genotypic and phenotypic analysis at the time of virological failure. For participants with a baseline viral load greater than (&gt;) 200 copies/mL, virologic failure was defined as follows: HIV ribonucleic acid (RNA) levels that did not fall by at least 0.5 log 4 weeks after Baseline; viral load &gt;1000 copies/mL (at 2 successive visits) by gestational weeks 34-38; or viral load &gt;200 copies/mL (at 2 successive visits) after reaching a viral load less than or equal to (&lt;=) 200 copies/mL. For participants with a baseline viral load &lt;=200 copies/mL, virologic failure was defined as viral load of &gt;200 copies/mL (at 2 successive visits) at any point during the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Drug in the Cord Plasma and Maternal Plasma Samples Collected at the Time of Delivery</measure>
    <time_frame>On day of delivery - Intrapartum (Visit 6)</time_frame>
    <description>The drug concentrations were evaluated in the cord plasma and maternal plasma samples collected at the time of delivery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Infants With Human Immunodeficiency Virus (HIV) Positive Test Result</measure>
    <time_frame>Birth to age 16 weeks</time_frame>
    <description>The infants were evaluated for HIV positive tests using HIV polymerase chain reaction test (PCR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to follow up period (16 weeks after postpartum)</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>HIV</condition>
  <condition>HIV Infections</condition>
  <condition>Pregnancy</condition>
  <arm_group>
    <arm_group_label>Group 1: Darunavir 600 /Ritonavir 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC114 (darunavir) Two 300 milligram (mg) or one 600 mg tablet twice daily up to 12 weeks postpartum / ritonavir one 100 mg tablet twice daily with darunavir up to 12 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: Darunavir 800/Ritonavir 100</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum/ ritonavir one 100 mg tablet once daily with darunavir up to 12 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: Etravirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC125 (etravirine) Two 200 mg tablets twice daily up to 12 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: Rilpivirine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TMC278 (rilpivirine) One 25 mg tablet once daily up to 12 weeks postpartum.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5: Darunavir 800/Cobicistat 150</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.</description>
    <arm_group_label>Group 1: Darunavir 600 /Ritonavir 100</arm_group_label>
    <arm_group_label>Group 2: Darunavir 800/Ritonavir 100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>100 mg tablet twice daily up to 12 weeks postpartum.</description>
    <arm_group_label>Group 1: Darunavir 600 /Ritonavir 100</arm_group_label>
    <arm_group_label>Group 2: Darunavir 800/Ritonavir 100</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etravirine</intervention_name>
    <description>Two 200 mg tablets twice daily up to 12 weeks postpartum.</description>
    <arm_group_label>Group 3: Etravirine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rilpivirine</intervention_name>
    <description>One 25 mg tablet once daily up to 12 weeks postpartum.</description>
    <arm_group_label>Group 4: Rilpivirine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir/Cobicistat (FDC)</intervention_name>
    <description>Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.</description>
    <arm_group_label>Group 5: Darunavir 800/Cobicistat 150</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant females (18-26 weeks of gestation)

          -  documented HIV-1 infection

          -  Receiving darunavir/ritonavir, darunavir/cobicistat, etravirine, or rilpivirine at the
             time of study entry

          -  Willing to remain on darunavir/ritonavir, darunavir/cobicistat, etravirine, or
             rilpivirine as well as a background regimen, for the duration of the study, including
             12 weeks postpartum

          -  Able to comply with the protocol requirements and to provide written informed consent.

        Exclusion Criteria:

          -  Patients with any currently active acquired immune deficiency syndrome (AIDS) defining
             illness and AIDS-related opportunistic infection

          -  Patients using cytokine inhibitors (e.g., thalidomide), anabolic hormones, cytokines
             (e.g., IL-2, INF), efavirenz, hydroxyurea, oral hypoglycemics, systemic chemotherapy
             or known teratogenic agent

          -  Use of an investigational agent within 90 days

          -  Any known fetal anomaly

          -  Any current obstetric complication, including multiple gestations and pre-term labor

          -  Hepatitis B and/or C virus infection

          -  Grade 2 or higher anemia

          -  Thyroid disease

          -  Uncontrolled Diabetes Mellitus Types I and II, or gestational diabetes, as determined
             by the investigator
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Scientific Affairs, LLC Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Scientific Affairs, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Saint Lucie</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Juan Pr</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2009</study_first_submitted>
  <study_first_submitted_qc>March 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2009</study_first_posted>
  <results_first_submitted>June 30, 2017</results_first_submitted>
  <results_first_submitted_qc>August 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 15, 2017</results_first_posted>
  <last_update_submitted>February 12, 2018</last_update_submitted>
  <last_update_submitted_qc>February 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1</keyword>
  <keyword>HIV</keyword>
  <keyword>Pregnancy</keyword>
  <keyword>Postpartum</keyword>
  <keyword>Human immunodeficiency virus</keyword>
  <keyword>PREZISTA</keyword>
  <keyword>INTELENCE</keyword>
  <keyword>NORVIR</keyword>
  <keyword>TMC114</keyword>
  <keyword>TMC125</keyword>
  <keyword>darunavir</keyword>
  <keyword>ritonavir</keyword>
  <keyword>etravirine</keyword>
  <keyword>rilpivirine</keyword>
  <keyword>TMC278</keyword>
  <keyword>Cobicistat</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Cobicistat</mesh_term>
    <mesh_term>Rilpivirine</mesh_term>
    <mesh_term>Etravirine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Darunavir 600 mg /Ritonavir 100 mg Twice Daily</title>
          <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="P2">
          <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
          <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="P3">
          <title>Etravirine 200 mg Twice Daily</title>
          <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="P4">
          <title>Rilpivirine 25 mg Once Daily</title>
          <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="P5">
          <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
          <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Darunavir 600 mg /Ritonavir 100 mg Twice Daily</title>
          <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="B2">
          <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
          <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="B3">
          <title>Etravirine 200 mg Twice Daily</title>
          <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="B4">
          <title>Rilpivirine 25 mg Once Daily</title>
          <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="B5">
          <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
          <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="17"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="19"/>
            <count group_id="B5" value="7"/>
            <count group_id="B6" value="75"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.7" spread="5.77"/>
                    <measurement group_id="B2" value="24.1" spread="3.55"/>
                    <measurement group_id="B3" value="26.3" spread="4.91"/>
                    <measurement group_id="B4" value="27.2" spread="4.51"/>
                    <measurement group_id="B5" value="28.86" spread="4.71"/>
                    <measurement group_id="B6" value="25.8" spread="4.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="15"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Predose (Trough) Plasma Concentration (C0h)</title>
        <description>C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.</description>
        <time_frame>Predose on Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
        <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) orally twice daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir 100 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally twice daily along with darunavir 600 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Darunavir 800 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) orally once daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Ritonavir 100 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally once daily along with darunavir 800 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O6">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O7">
            <title>Darunavir 800 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg along with cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O8">
            <title>Cobicistat 150 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received cobicistat 150 mg along with darunavir 800 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Predose (Trough) Plasma Concentration (C0h)</title>
          <description>C0h is defined as the predose (trough) plasma concentration or concentration just prior to study drug administration.</description>
          <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postpartum (6-12 W)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3497" spread="2922"/>
                    <measurement group_id="O2" value="418.8" spread="419.4"/>
                    <measurement group_id="O3" value="2647" spread="2153"/>
                    <measurement group_id="O4" value="157" spread="200"/>
                    <measurement group_id="O5" value="281" spread="193"/>
                    <measurement group_id="O6" value="127" spread="97.0"/>
                    <measurement group_id="O7" value="2811" spread="2296"/>
                    <measurement group_id="O8" value="134" spread="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2403" spread="1161"/>
                    <measurement group_id="O2" value="241.0" spread="120.4"/>
                    <measurement group_id="O3" value="1745" spread="976"/>
                    <measurement group_id="O4" value="85.5" spread="98.7"/>
                    <measurement group_id="O5" value="439" spread="212"/>
                    <measurement group_id="O6" value="75.6" spread="36.2"/>
                    <measurement group_id="O7" value="540" spread="803"/>
                    <measurement group_id="O8" value="NA">Here, NA indicates that the data is not reported because the predose plasma concentrations were Below Quantification Limit (BQL) less than (&lt;) 5.00 ng/mL.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3028" spread="1236"/>
                    <measurement group_id="O2" value="210.2" spread="63.64"/>
                    <measurement group_id="O3" value="1584" spread="1208"/>
                    <measurement group_id="O4" value="78.2" spread="92.5"/>
                    <measurement group_id="O5" value="413" spread="78.2"/>
                    <measurement group_id="O6" value="78.0" spread="39.1"/>
                    <measurement group_id="O7" value="824" spread="630"/>
                    <measurement group_id="O8" value="30.1" spread="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimum Plasma Concentration (Cmin)</title>
        <description>The Cmin is the minimum observed plasma concentration.</description>
        <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
        <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) orally twice daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir 100 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally twice daily along with darunavir 600 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Darunavir 800 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) orally once daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Ritonavir 100 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally once daily along with darunavir 800 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O6">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O7">
            <title>Darunavir 800 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg along with cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O8">
            <title>Cobicistat 150 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received cobicistat 150 mg along with darunavir 800 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimum Plasma Concentration (Cmin)</title>
          <description>The Cmin is the minimum observed plasma concentration.</description>
          <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postpartum (6-12 W)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2711" spread="2268"/>
                    <measurement group_id="O2" value="232.5" spread="246.1"/>
                    <measurement group_id="O3" value="1572" spread="1108"/>
                    <measurement group_id="O4" value="43.2" spread="30.5"/>
                    <measurement group_id="O5" value="269" spread="182"/>
                    <measurement group_id="O6" value="84.0" spread="58.8"/>
                    <measurement group_id="O7" value="1538" spread="1344"/>
                    <measurement group_id="O8" value="41.4" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1980" spread="840"/>
                    <measurement group_id="O2" value="149.7" spread="69.92"/>
                    <measurement group_id="O3" value="1193" spread="509"/>
                    <measurement group_id="O4" value="30.0" spread="18.0"/>
                    <measurement group_id="O5" value="383" spread="210"/>
                    <measurement group_id="O6" value="54.3" spread="25.8"/>
                    <measurement group_id="O7" value="168" spread="149"/>
                    <measurement group_id="O8" value="NA">Here, NA indicates that the data is not reported because the plasma concentrations were BQL (&lt; 5.00 ng/mL).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2498" spread="1193"/>
                    <measurement group_id="O2" value="137.1" spread="39.47"/>
                    <measurement group_id="O3" value="1098" spread="609"/>
                    <measurement group_id="O4" value="28.3" spread="21.2"/>
                    <measurement group_id="O5" value="349" spread="103"/>
                    <measurement group_id="O6" value="52.9" spread="24.4"/>
                    <measurement group_id="O7" value="184" spread="99.0"/>
                    <measurement group_id="O8" value="NA">Here, NA indicates that the data is not reported because the plasma concentrations were BQL (&lt; 5.00 ng/mL).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration (Cmax)</title>
        <description>The Cmax is the maximum observed plasma concentration.</description>
        <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
        <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) orally twice daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir 100 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally twice daily along with darunavir 600 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Darunavir 800 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) orally once daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Ritonavir 100 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally once daily along with darunavir 800 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O6">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O7">
            <title>Darunavir 800 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg along with cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O8">
            <title>Cobicistat 150 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received cobicistat 150 mg along with darunavir 800 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax)</title>
          <description>The Cmax is the maximum observed plasma concentration.</description>
          <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postpartum (6-12 W)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6499" spread="2411"/>
                    <measurement group_id="O2" value="1016" spread="881.8"/>
                    <measurement group_id="O3" value="7445" spread="1674"/>
                    <measurement group_id="O4" value="729" spread="343"/>
                    <measurement group_id="O5" value="569" spread="261"/>
                    <measurement group_id="O6" value="167" spread="101"/>
                    <measurement group_id="O7" value="7918" spread="2199"/>
                    <measurement group_id="O8" value="996" spread="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4601" spread="1125"/>
                    <measurement group_id="O2" value="569.8" spread="245.6"/>
                    <measurement group_id="O3" value="4988" spread="1551"/>
                    <measurement group_id="O4" value="419" spread="235"/>
                    <measurement group_id="O5" value="774" spread="300"/>
                    <measurement group_id="O6" value="121" spread="45.9"/>
                    <measurement group_id="O7" value="4340" spread="1616"/>
                    <measurement group_id="O8" value="571" spread="350"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5111" spread="1517"/>
                    <measurement group_id="O2" value="515.3" spread="206.4"/>
                    <measurement group_id="O3" value="5138" spread="1243"/>
                    <measurement group_id="O4" value="377" spread="172"/>
                    <measurement group_id="O5" value="785" spread="238"/>
                    <measurement group_id="O6" value="123" spread="47.5"/>
                    <measurement group_id="O7" value="4910" spread="970"/>
                    <measurement group_id="O8" value="759" spread="366"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time to Reach the Maximum Plasma Concentration (Tmax)</title>
        <description>The Tmax is defined as actual sampling time to reach maximum observed plasma concentration.</description>
        <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
        <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) orally twice daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir 100 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally twice daily along with darunavir 600 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Darunavir 800 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) orally once daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Ritonavir 100 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally once daily along with darunavir 800 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O6">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O7">
            <title>Darunavir 800 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg along with cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O8">
            <title>Cobicistat 150 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received cobicistat 150 mg along with darunavir 800 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Reach the Maximum Plasma Concentration (Tmax)</title>
          <description>The Tmax is defined as actual sampling time to reach maximum observed plasma concentration.</description>
          <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>hour (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="13"/>
                <count group_id="O6" value="15"/>
                <count group_id="O7" value="7"/>
                <count group_id="O8" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postpartum (6-12 W)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="11"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O2" value="6.00" lower_limit="2.02" upper_limit="12.08"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.28" lower_limit="2.02" upper_limit="6.03"/>
                    <measurement group_id="O5" value="4.00" lower_limit="1.00" upper_limit="9.00"/>
                    <measurement group_id="O6" value="4.00" lower_limit="2.03" upper_limit="25.08"/>
                    <measurement group_id="O7" value="4.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="4.00" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="15"/>
                    <count group_id="O7" value="7"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="0.93" upper_limit="5.83"/>
                    <measurement group_id="O2" value="4.14" lower_limit="0.93" upper_limit="6.08"/>
                    <measurement group_id="O3" value="4.00" lower_limit="3.00" upper_limit="6.08"/>
                    <measurement group_id="O4" value="5.96" lower_limit="2.03" upper_limit="6.10"/>
                    <measurement group_id="O5" value="3.05" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O6" value="4.00" lower_limit="1.00" upper_limit="9.00"/>
                    <measurement group_id="O7" value="4.00" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="4.03" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="13"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="11.88"/>
                    <measurement group_id="O2" value="4.05" lower_limit="1.00" upper_limit="9.10"/>
                    <measurement group_id="O3" value="3.53" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="6.01" lower_limit="2.02" upper_limit="6.02"/>
                    <measurement group_id="O5" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O6" value="4.00" lower_limit="2.00" upper_limit="24.93"/>
                    <measurement group_id="O7" value="3.50" lower_limit="2.00" upper_limit="6.00"/>
                    <measurement group_id="O8" value="3.50" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 Hours Post-dose (AUC0-12h)</title>
        <description>The AUC (0-12) is the area under the plasma concentration-time curve from time zero to 12 hours post dose. The selected arms were based on the dosing frequency (twice daily).</description>
        <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
        <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) orally twice daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir 100 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally twice daily along with darunavir 600 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time of Administration to 12 Hours Post-dose (AUC0-12h)</title>
          <description>The AUC (0-12) is the area under the plasma concentration-time curve from time zero to 12 hours post dose. The selected arms were based on the dosing frequency (twice daily).</description>
          <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postpartum (6-12 W)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55300" spread="27020"/>
                    <measurement group_id="O2" value="6746" spread="6032"/>
                    <measurement group_id="O3" value="5004" spread="2521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38950" spread="10010"/>
                    <measurement group_id="O2" value="3929" spread="1203"/>
                    <measurement group_id="O3" value="6617" spread="2766"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd Trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43700" spread="16400"/>
                    <measurement group_id="O2" value="3532" spread="1130"/>
                    <measurement group_id="O3" value="6846" spread="1482"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h)</title>
        <description>The AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post dose. The selected arms were based on the dosing frequency (once daily).</description>
        <time_frame>Between Predose and 24 hours postdose at Weeks 24-28 (Visit 4, 2nd trimester), 34-38 (visit 5, 3rd trimester) and 6-12 weeks postpartum (visit 8)</time_frame>
        <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 800 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) orally once daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir 100 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally once daily along with darunavir 800 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Darunavir 800 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg along with cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Cobicistat 150 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received cobicistat 150 mg along with darunavir 800 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time of Administration to 24 Hours Post-dose (AUC0-24h)</title>
          <description>The AUC (0-24) is the area under the plasma concentration-time curve from time zero to 24 hours post dose. The selected arms were based on the dosing frequency (once daily).</description>
          <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram*hour per milliliter (ng*h/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Postpartum (6-12 W)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94529" spread="28572"/>
                    <measurement group_id="O2" value="3692" spread="1861"/>
                    <measurement group_id="O3" value="2714" spread="1535"/>
                    <measurement group_id="O4" value="99613" spread="34862"/>
                    <measurement group_id="O5" value="8643" spread="3187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61303" spread="16232"/>
                    <measurement group_id="O2" value="3601" spread="1555"/>
                    <measurement group_id="O3" value="1792" spread="711"/>
                    <measurement group_id="O4" value="47293" spread="19058"/>
                    <measurement group_id="O5" value="3862" spread="2703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60439" spread="14052"/>
                    <measurement group_id="O2" value="6566" spread="2960"/>
                    <measurement group_id="O3" value="1762" spread="662"/>
                    <measurement group_id="O4" value="47991" spread="9879"/>
                    <measurement group_id="O5" value="4736" spread="2917"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Plasma Viral Load (&lt;) 50 Copies/Milliliter (mL)</title>
        <description>Number of participants were assessed with a viral load (VL) lesser than (&lt;) 50 HIV-1 RNA copies/ mL over time.</description>
        <time_frame>Up to postpartum (6-12 weeks)</time_frame>
        <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg /Ritonavir 100 Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
            <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Plasma Viral Load (&lt;) 50 Copies/Milliliter (mL)</title>
          <description>Number of participants were assessed with a viral load (VL) lesser than (&lt;) 50 HIV-1 RNA copies/ mL over time.</description>
          <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>2nd trimester Less than(&lt;)50 copies/milliLiter(mL)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd trimester: &lt;50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postpartum (2-5 weeks): &lt;50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postpartum (6-12 weeks): &lt;50 copies/mL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="10"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Log10 Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Viral Load Value</title>
        <description>Mean change from baseline in log 10 HIV-1 RNA VL was assessed up to postpartum (6-12 weeks).</description>
        <time_frame>Baseline, 4 weeks after baseline, 2nd and 3rd trimesters of pregnancy and postpartum (2-5 weeks and 6-12 weeks)</time_frame>
        <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg /Ritonavir 100 Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
            <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Log10 Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Viral Load Value</title>
          <description>Mean change from baseline in log 10 HIV-1 RNA VL was assessed up to postpartum (6-12 weeks).</description>
          <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>Log 10 copies per milliliter (copies/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.14" spread="0.189"/>
                    <measurement group_id="O2" value="1.90" spread="0.094"/>
                    <measurement group_id="O3" value="2.06" spread="0.206"/>
                    <measurement group_id="O4" value="1.84" spread="0.159"/>
                    <measurement group_id="O5" value="1.77" spread="0.283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks after Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" spread="0.161"/>
                    <measurement group_id="O2" value="-0.27" spread="0.145"/>
                    <measurement group_id="O3" value="0.18" spread="0.182"/>
                    <measurement group_id="O4" value="0.20" spread="0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.113"/>
                    <measurement group_id="O2" value="-0.17" spread="0.110"/>
                    <measurement group_id="O3" value="0.16" spread="0.084"/>
                    <measurement group_id="O4" value="0.16" spread="0.074"/>
                    <measurement group_id="O5" value="0.1" spread="0.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.34" spread="0.113"/>
                    <measurement group_id="O2" value="-0.25" spread="0.111"/>
                    <measurement group_id="O3" value="0.17" spread="0.105"/>
                    <measurement group_id="O4" value="0.25" spread="0.113"/>
                    <measurement group_id="O5" value="0.21" spread="0.326"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postpartum (2-5 weeks)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.20" spread="0.121"/>
                    <measurement group_id="O2" value="-0.04" spread="0.156"/>
                    <measurement group_id="O3" value="0.13" spread="0.168"/>
                    <measurement group_id="O4" value="0.20" spread="0.273"/>
                    <measurement group_id="O5" value="0.18" spread="0.304"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postpartum (6-12 weeks)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="0.291"/>
                    <measurement group_id="O2" value="-0.07" spread="0.211"/>
                    <measurement group_id="O3" value="0.05" spread="0.058"/>
                    <measurement group_id="O4" value="0.08" spread="0.138"/>
                    <measurement group_id="O5" value="0.23" spread="0.347"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in CD4+ Cell Count</title>
        <description>Mean Change From Baseline in CD4+ Cell Count were assessed for immunology testing.</description>
        <time_frame>Baseline, 4 weeks after baseline, 2nd and 3rd trimesters of pregnancy and postpartum (2-5 weeks and 6-12 weeks)</time_frame>
        <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication. Here 'N' signified number of participants evaluated for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg /Ritonavir 100 Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
            <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in CD4+ Cell Count</title>
          <description>Mean Change From Baseline in CD4+ Cell Count were assessed for immunology testing.</description>
          <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication. Here 'N' signified number of participants evaluated for this outcome measure.</population>
          <units>10^6 Cells/Liter</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="19"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="451.3" spread="49.96"/>
                    <measurement group_id="O2" value="522.2" spread="63.52"/>
                    <measurement group_id="O3" value="417.47" spread="80.469"/>
                    <measurement group_id="O4" value="495.79" spread="79.322"/>
                    <measurement group_id="O5" value="594.17" spread="108.151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks after Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="23.16"/>
                    <measurement group_id="O2" value="116.3" spread="62.41"/>
                    <measurement group_id="O3" value="6.25" spread="26.004"/>
                    <measurement group_id="O4" value="24.00" spread="56.912"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2nd trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="16"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="14"/>
                    <count group_id="O5" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="24.92"/>
                    <measurement group_id="O2" value="163.4" spread="45.87"/>
                    <measurement group_id="O3" value="13.77" spread="53.225"/>
                    <measurement group_id="O4" value="39.21" spread="36.496"/>
                    <measurement group_id="O5" value="13.29" spread="34.445"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3rd trimester</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="13"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" spread="32.00"/>
                    <measurement group_id="O2" value="291.9" spread="67.85"/>
                    <measurement group_id="O3" value="77.30" spread="30.803"/>
                    <measurement group_id="O4" value="89.46" spread="26.137"/>
                    <measurement group_id="O5" value="72.17" spread="62.882"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postpartum (2-5 weeks)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.7" spread="30.86"/>
                    <measurement group_id="O2" value="191.9" spread="46.0"/>
                    <measurement group_id="O3" value="115.36" spread="33.584"/>
                    <measurement group_id="O4" value="139.42" spread="36.972"/>
                    <measurement group_id="O5" value="163" spread="37.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Postpartum (6-12 weeks)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.9" spread="46.27"/>
                    <measurement group_id="O2" value="341.6" spread="65.45"/>
                    <measurement group_id="O3" value="154.90" spread="54.131"/>
                    <measurement group_id="O4" value="168.18" spread="41.345"/>
                    <measurement group_id="O5" value="244.67" spread="100.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Resistance at Virological Failure</title>
        <description>Resistance analysis was determined using genotypic and phenotypic analysis at the time of virological failure. For participants with a baseline viral load greater than (&gt;) 200 copies/mL, virologic failure was defined as follows: HIV ribonucleic acid (RNA) levels that did not fall by at least 0.5 log 4 weeks after Baseline; viral load &gt;1000 copies/mL (at 2 successive visits) by gestational weeks 34-38; or viral load &gt;200 copies/mL (at 2 successive visits) after reaching a viral load less than or equal to (&lt;=) 200 copies/mL. For participants with a baseline viral load &lt;=200 copies/mL, virologic failure was defined as viral load of &gt;200 copies/mL (at 2 successive visits) at any point during the study.</description>
        <time_frame>Up to follow-up phase (16 weeks after postpartum)</time_frame>
        <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg /Ritonavir 100 Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
            <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Resistance at Virological Failure</title>
          <description>Resistance analysis was determined using genotypic and phenotypic analysis at the time of virological failure. For participants with a baseline viral load greater than (&gt;) 200 copies/mL, virologic failure was defined as follows: HIV ribonucleic acid (RNA) levels that did not fall by at least 0.5 log 4 weeks after Baseline; viral load &gt;1000 copies/mL (at 2 successive visits) by gestational weeks 34-38; or viral load &gt;200 copies/mL (at 2 successive visits) after reaching a viral load less than or equal to (&lt;=) 200 copies/mL. For participants with a baseline viral load &lt;=200 copies/mL, virologic failure was defined as viral load of &gt;200 copies/mL (at 2 successive visits) at any point during the study.</description>
          <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Drug in the Cord Plasma and Maternal Plasma Samples Collected at the Time of Delivery</title>
        <description>The drug concentrations were evaluated in the cord plasma and maternal plasma samples collected at the time of delivery.</description>
        <time_frame>On day of delivery - Intrapartum (Visit 6)</time_frame>
        <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg (Darunavir 600/Ritonavir 100) Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) orally twice daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Ritonavir 100 mg (Darunavir 600/Ritonavir 100 mg) Twice Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally twice daily along with darunavir 600 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Darunavir 800 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) orally once daily along with ritonavir 100 mg up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Ritonavir 100 mg (Darunavir 800/Ritonavir 100 mg) Once Daily</title>
            <description>Participants received ritonavir 100 mg capsules orally once daily along with darunavir 800 mg tablets up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O6">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O7">
            <title>Darunavir 800 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received darunavir 800 mg along with cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O8">
            <title>Cobicistat 150 mg (Darunavir 800/Cobicistat 150 mg) Once Daily</title>
            <description>Participants received cobicistat 150 mg along with darunavir 800 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Drug in the Cord Plasma and Maternal Plasma Samples Collected at the Time of Delivery</title>
          <description>The drug concentrations were evaluated in the cord plasma and maternal plasma samples collected at the time of delivery.</description>
          <population>Population analyzed included participants who received at least one dose of study drug with at least one PK blood sample available. Arms were created to report data separately for the treatments and analytes. Here ‘N’ signifies number of participants evaluable for this outcome measure.</population>
          <units>nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="16"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="5"/>
                <count group_id="O8" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cord Plasma: (n= 10, 7, 16, 16, 10, 8)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="10"/>
                    <count group_id="O6" value="8"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="348.4" spread="322.90"/>
                    <measurement group_id="O2" value="17.07" spread="23.98"/>
                    <measurement group_id="O3" value="228" spread="302"/>
                    <measurement group_id="O4" value="NA">The data was not analyzed in case either the cord or maternal plasma concentration was below quantification limit (lesser than (&lt;) 5.00 ng/mL).</measurement>
                    <measurement group_id="O5" value="147" spread="61.3"/>
                    <measurement group_id="O6" value="32.8" spread="16.7"/>
                    <measurement group_id="O7" value="125" spread="106"/>
                    <measurement group_id="O8" value="NA">The data was not analyzed in case either the cord or maternal plasma concentration was below quantification limit (lesser than (&lt;) 5.00 ng/mL).</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maternal Plasma: (n= 10, 10, 16, 16, 11, 9)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="16"/>
                    <count group_id="O5" value="11"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="5"/>
                    <count group_id="O8" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2149" spread="1140"/>
                    <measurement group_id="O2" value="316.7" spread="394.4"/>
                    <measurement group_id="O3" value="1663" spread="1691"/>
                    <measurement group_id="O4" value="154" spread="274"/>
                    <measurement group_id="O5" value="421" spread="157"/>
                    <measurement group_id="O6" value="59.0" spread="34.7"/>
                    <measurement group_id="O7" value="857" spread="885"/>
                    <measurement group_id="O8" value="74.5" spread="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Infants With Human Immunodeficiency Virus (HIV) Positive Test Result</title>
        <description>The infants were evaluated for HIV positive tests using HIV polymerase chain reaction test (PCR).</description>
        <time_frame>Birth to age 16 weeks</time_frame>
        <population>Infants population whose mothers were included in Intent-to-treat (ITT) analysis set and who were enrolled in this study and took at least one dose of study medication. 'N' signifies number of infants who were born and had HIV test data available.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg /Ritonavir 100 Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
            <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Infants With Human Immunodeficiency Virus (HIV) Positive Test Result</title>
          <description>The infants were evaluated for HIV positive tests using HIV polymerase chain reaction test (PCR).</description>
          <population>Infants population whose mothers were included in Intent-to-treat (ITT) analysis set and who were enrolled in this study and took at least one dose of study medication. 'N' signifies number of infants who were born and had HIV test data available.</population>
          <units>infants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Up to follow up period (16 weeks after postpartum)</time_frame>
        <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Darunavir 600 mg /Ritonavir 100 Twice Daily</title>
            <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O2">
            <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
            <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O3">
            <title>Etravirine 200 mg Twice Daily</title>
            <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O4">
            <title>Rilpivirine 25 mg Once Daily</title>
            <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
          </group>
          <group group_id="O5">
            <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
            <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="19"/>
                <count group_id="O5" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to Follow up phase (16 weeks after postpartum)</time_frame>
      <desc>Intent-to-treat (ITT) analysis set is defined as all participants enrolled in this study who took at least one dose of study medication. The Adverse events were reported as per MedDRA Version 11.1 for darunavir and rilpivirine ; MeDRA version 16.0 for etravirine.</desc>
      <group_list>
        <group group_id="E1">
          <title>Darunavir 600 mg /Ritonavir 100 mg Twice Daily</title>
          <description>Participants received darunavir 600 milligram (mg) tablets (300*2) and ritonavir 100 mg capsules orally twice daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="E2">
          <title>Darunavir 800 mg /Ritonavir 100 mg Once Daily</title>
          <description>Participants received darunavir 800 mg tablets (400*2) and ritonavir 100 mg capsules orally once daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="E3">
          <title>Etravirine 200 mg Twice Daily</title>
          <description>Participants received etravirine 200 mg (100*2) tablets orally twice daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="E4">
          <title>Rilpivirine 25 mg Once Daily</title>
          <description>Participants received tablets containing 25 mg rilpivirine (EDURANT or COMPLERA) orally once daily up to 12 weeks postpartum.</description>
        </group>
        <group group_id="E5">
          <title>Darunavir 800 mg/Cobicistat 150 mg Once Daily</title>
          <description>Participants received darunavir 800 mg and Cobicistat 150 mg in a fixed-dose combination (FDC) as film-coated tablet formulation (PREZCOBIX) orally once daily up to 12 weeks postpartum.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 11.1 and 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Medical Observation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gestational Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Chorioamnionitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Intra-Uterine Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oligohydramnios</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pre-Eclampsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pregnancy Induced Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Premature Labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Premature Rupture of Membranes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 11.1 and 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Anaemia of Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision Blurred</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Lower</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pitting Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fungal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Genital Herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tinea Pedis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vaginal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vaginitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Mycotic Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eye Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood Albumin Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood Amylase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood Thyroid Stimulating Hormone Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac Murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lipase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Methicillin-Resistant Staphylococcal Aureus Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Streptococcal Identification Test Positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Transaminases Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>High Density Lipoprotein Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gestational Diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal Tunnel Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Migraine with Aura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Poor Quality Sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Chorioamnionitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Labour Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Postpartum Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pregnancy Induced Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Premature Labour</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Uterine Contractions During Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Major Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Postpartum Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital Discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vaginal Discharge</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pelvic Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis Atopic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin Exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>If an investigator wishes to publish information from the study, a copy of the manuscript must be provided to the sponsor for review at least 60 days before submission for publication or presentation. If requested in writing, such publication will be withheld for up to an additional 60 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Leader, Medical Department</name_or_title>
      <organization>Janssen Scientific Affairs, LLC</organization>
      <email>ClinicalTrialDisclosure@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

